Formulation Development
Exeliom Biosciences Announces Three Phase 2 Clinical Trials in Immuno-oncology With Lead Candidate Combined With Immune Checkpoint Inhibitors
Exeliom Biosciences recently announced the launch of three Phase 2 clinical studies of its lead candidate EXL01 combined with immune checkpoint inhibitors to target multiple…
Athira Pharma Announces Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma, Inc. recently announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, Fosgonimeton Attenuates…
Arvinas Enters Transaction With Novartis, Including Global License Agreement for the Development & Commercialization of Androgen Receptor Protein Degrader
Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer….
Century Therapeutics Strengthens Position in Autoimmune Disease With Strategic Pipeline Expansion Supported by $60-Million Private Placement & Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile….
MoonLake Immunotherapeutics Signs 3-Year Technology Partnership With Komodo Health
MoonLake Immunotherapeutics and Komodo Health recently announced a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The…
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed AG recently announced the US FDA granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment…
Silo Pharma Set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license Alzheimer’s disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement….
Palisade Bio Presents Development Overview for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it presented at IBD Innovate: Product Development for Crohn’s & Colitis held April 9-10, 2024, in Cambridge, MA. As part…
IO Biotech Presents New Data Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine
IO Biotech recently shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the 2004 American Association for Cancer Research (AACR)…
NeuroSense Collaborates With Lonza to Identify Exosome-Based Biomarkers to Advance Neurodegenerative Disease Treatments & Diagnostics
Lonza and NeuroSense Therapeutics Ltd. recently announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. This agreement provides NeuroSense…
Essential Pharma Acquires Renaissance Pharma With its Clinical-Stage Immunotherapy
Essential Pharma recently announced it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance Pharma is a clinical-stage pharmaceutical…
4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
Long-Term Partnership Agreed with Beacon Therapeutics for Clinical and Commercial AAV Production….
INmune Bio Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer
INmune Bio, Inc. recently presented data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment…
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases
MiNK Therapeutics, Inc. recently announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the…
AustinPx Invests in Pharmaceutics & Manufacturing Capabilities to Accelerate Drug Development
AustinPx recently announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer, and the STYL’One Nano compaction simulator. The…
Biora Therapeutics Announces New Patent Covering its BioJet Liquid Jet Delivery Technology
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract….
Ocugen Announces FDA Clearance of IND Amendment to Initiate Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 With a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400,…
PolTREG Identifies Promising Efficacy Biomarker for Type-1 Diabetes in Patients Treated With its Treg Therapy in Combination With Rituximab
PolTREG S.A. recemtly announced it has published data in International Immunopharmacology, which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset…
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which…
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Biora Therapeutics, Inc. recently shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of…
